

---

**Name of the Issue: Dr. Agarwal's Health Care Limited**

**1 Type of Issue** Initial Public Offer

**2 Issue Size (Rs. Mn)** 30,272.60\*

*\*Source: Basis of Allotment*

**3 Grade of issue along with name of the rating agency**

**Name** Not Applicable

**Grade** Not Applicable

**4 Subscription Level (Number of times)** 1.55

*\*The above figure is after technical rejection and excludes anchor allotment*

*Source: Basis of allotment*

**5 QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges**

| Particulars                                  | %      |
|----------------------------------------------|--------|
| (i) On Allotment *                           | 62.07% |
| (iii) at the end of 1st FY (March 31, 2025)  | 65.83% |
| (iv) at the end of 2nd FY (March 31, 2026)** | N.A.   |
| (v) at the end of 3rd FY (March 31, 2027)**  | N.A.   |

*\*Shareholding pattern disclosed to Stock Exchanges*

*\*\* QIB Holding not disclosed as reporting for relevant period has not been completed.*

**6 Financials of the issuer**

*(Rs. Million)*

| Parameters                              | 1st FY (March 31, 2025) | 2nd FY (March 31, 2026) * | 3rd FY (March 31, 2027) * |
|-----------------------------------------|-------------------------|---------------------------|---------------------------|
| Income from operations                  | 17,110                  | Not Available             | Not Available             |
| Net Profit for the period               | 1,098                   | Not Available             | Not Available             |
| Paid-up equity share capital            | 316                     | Not Available             | Not Available             |
| Reserves excluding revaluation reserves | 18,350                  | Not Available             | Not Available             |

*\* Financials not available as reporting for the relevant years has not been completed.*

## 7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")  
The equity shares have not been suspended or delisted.

| Particulars                                   | Status            |
|-----------------------------------------------|-------------------|
| (i) at the end of 1st FY (March 31, 2025)     | Frequently Traded |
| (ii) at the end of 2nd FY (March 31, 2026) *  | Not Available     |
| (iii) at the end of 3rd FY (March 31, 2027) * | Not Available     |

*\* Trading status not disclosed as the relevant fiscal years have not been completed.*

## 8 Change in Directors of Issuer from the disclosures in the offer document

| Particulars                                   | Name of Director | Appointed / Resigned |
|-----------------------------------------------|------------------|----------------------|
| (i) at the end of 1st FY (March 31, 2025)     | Not Available    | Not Available        |
| (ii) at the end of 2nd FY (March 31, 2026) *  | Not Available    | Not Available        |
| (iii) at the end of 3rd FY (March 31, 2027) * | Not Available    | Not Available        |

*\* Changes in Directors of Issuer not updated as the relevant financial years have not been completed*

## 9 Status of implementation of project/ commencement of commercial production

|                                                   |                |
|---------------------------------------------------|----------------|
| (i) as disclosed in the offer document            | Not applicable |
| (ii) Actual implementation                        | Not applicable |
| (iii) Reasons for delay in implementation, if any | Not applicable |

## 10 Status of utilization of issue proceeds

|                                        |                                                                                           |
|----------------------------------------|-------------------------------------------------------------------------------------------|
| (i) As disclosed in the offer document | (i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1,950.00 mn) |
|                                        | (ii) General corporate purposes (INR 774.66 mn)                                           |
| (ii) Actual utilization                | (i) Repayment/prepayment, in part or full, of certain of our borrowings (INR 1281.03 mn)  |
|                                        | (ii) General corporate purposes (INR 32.28 mn)                                            |
| (iii) Reasons for deviation, if any    | NA*                                                                                       |

*\*Will be updated once monitoring report is uploaded on the Stock Exchanges website*

---

## 11 Comments of monitoring agency, if applicable

|                                                                                                                        |                |
|------------------------------------------------------------------------------------------------------------------------|----------------|
| (i) Comments on use of funds                                                                                           | Not available* |
| (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document | Not available* |
| (iii) Any other reservations expressed by the monitoring agency about the end use of funds                             | Not available* |

*\*Will be updated once monitoring report is uploaded on the Stock Exchanges website*

## 12 Pricing Data

Designated Stock Exchange BSE  
Issue Price (Rs.) 402.00  
Listing Date 4-Feb-25

| Price parameters | At close of listing day- 04-Feb-25                                             | Close of 30th calendar day from listing day | Close of 90th calendar day from listing day | As at the end of the 1st FY after the listing of the issue (31st March, 2025)  |                |                |
|------------------|--------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------------------------------------------|----------------|----------------|
|                  |                                                                                |                                             |                                             | Closing price                                                                  | High           | Low            |
| Market Price     | 401.55                                                                         | 405.35                                      | 349.60                                      | 446.90                                                                         | 463.85         | 370.10         |
| Sensex           | 78,583.81                                                                      | 72,989.93                                   | 80,796.84                                   | 77,414.92                                                                      | 85,978.25      | 70,234.43      |
| Price parameters | As at the end of the 2nd FY after the listing of the issue (31st March, 2026)* |                                             |                                             | As at the end of the 3rd FY after the listing of the issue (31st March, 2027)* |                |                |
|                  | Closing price                                                                  | High                                        | Low                                         | Closing price                                                                  | High           | Low            |
| Market Price     | Not available*                                                                 | Not available*                              | Not available*                              | Not available*                                                                 | Not available* | Not available* |
| Sensex           | Not available*                                                                 | Not available*                              | Not available*                              | Not available*                                                                 | Not available* | Not available* |

\* The pricing data is not disclosed as the relevant fiscal years have not been completed

## 13 Basis for Issue Price

| Accounting ratio | As disclosed in the Prospectus                       | At the end of 1st FY (March 31, 2025) | At the end of 1st FY (March 31, 2026)*** | At the end of 1st FY (March 31, 2027)*** |
|------------------|------------------------------------------------------|---------------------------------------|------------------------------------------|------------------------------------------|
| EPS (Basic)      | <b>Company*</b>                                      | 3.14                                  | 2.80                                     |                                          |
|                  | <b>Peer Group &amp; Industry Avg**</b>               |                                       | 27.30                                    |                                          |
|                  | <i>Apollo Hospitals Enterprise Limited</i>           | 62.50                                 | 100.56                                   |                                          |
|                  | <i>Max Healthcare Institute Limited</i>              | 10.89                                 | 11.07                                    |                                          |
|                  | <i>Fortis Healthcare Limited</i>                     | 7.93                                  | 10.26                                    |                                          |
|                  | <i>Global Health Limited</i>                         | 17.80                                 | 17.92                                    |                                          |
|                  | <i>Narayana Hrudayalaya Limited</i>                  | 38.86                                 | 38.86                                    |                                          |
|                  | <i>Krishna Institute of Medical Sciences Limited</i> | 7.75                                  | 9.61                                     |                                          |
|                  | <i>Aster DM Healthcare Limited</i>                   | 3.60                                  | 6.16                                     |                                          |
|                  | <i>Rainbow Children's Medicare Limited</i>           | 21.38                                 | 23.97                                    |                                          |
| EPS (Diluted)    | <b>Company*</b>                                      | 3.13                                  | 2.78                                     | Not Available                            |
|                  | <b>Peer Group &amp; Industry Avg**</b>               |                                       | 27.28                                    | Not Available                            |
|                  | <i>Apollo Hospitals Enterprise Limited</i>           | 62.50                                 | 100.56                                   |                                          |
|                  | <i>Max Healthcare Institute Limited</i>              | 10.84                                 | 11.01                                    |                                          |
|                  | <i>Fortis Healthcare Limited</i>                     | 7.93                                  | 10.26                                    |                                          |
|                  | <i>Global Health Limited</i>                         | 17.80                                 | 17.92                                    |                                          |
|                  | <i>Narayana Hrudayalaya Limited</i>                  | 38.86                                 | 38.86                                    |                                          |
|                  | <i>Krishna Institute of Medical Sciences Limited</i> | 7.75                                  | 9.61                                     |                                          |
|                  | <i>Aster DM Healthcare Limited</i>                   | 3.60                                  | 6.16                                     |                                          |
|                  | <i>Rainbow Children's Medicare Limited</i>           | 21.38                                 | 23.84                                    |                                          |
| P/E              | <b>Company*</b>                                      | -                                     | 159.14                                   | Not Available                            |
|                  | <b>Peer Group &amp; Industry Avg**</b>               |                                       | 68.48                                    | Not Available                            |
|                  | <i>Apollo Hospitals Enterprise Limited</i>           | 107.11                                | 65.85                                    |                                          |
|                  | <i>Max Healthcare Institute Limited</i>              | 95.88                                 | 99.61                                    |                                          |
|                  | <i>Fortis Healthcare Limited</i>                     | 82.11                                 | 68.08                                    |                                          |
|                  | <i>Global Health Limited</i>                         | 57.49                                 | 66.86                                    |                                          |
|                  | <i>Narayana Hrudayalaya Limited</i>                  | 33.14                                 | 43.52                                    |                                          |
|                  | <i>Krishna Institute of Medical Sciences Limited</i> | 79.79                                 | 66.52                                    |                                          |
|                  | <i>Aster DM Healthcare Limited</i>                   | 136.07                                | 78.70                                    |                                          |
|                  | <i>Rainbow Children's Medicare Limited</i>           | 67.90                                 | 58.71                                    |                                          |

|               |                                                      |        |         |               |               |
|---------------|------------------------------------------------------|--------|---------|---------------|---------------|
| RONW          | <b>Company*</b>                                      | 6.21%  | 5.88%   | Not Available | Not Available |
|               | <b>Peer Group &amp; Industry Avg**</b>               |        | 33.66%  | Not Available | Not Available |
|               | <i>Apollo Hospitals Enterprise Limited</i>           | 12.97% | 18.25%  |               |               |
|               | <i>Max Healthcare Institute Limited</i>              | 12.58% | 11.42%  |               |               |
|               | <i>Fortis Healthcare Limited</i>                     | 7.82%  | 9.04%   |               |               |
|               | <i>Global Health Limited</i>                         | 16.46% | 14.19%  |               |               |
|               | <i>Narayana Hrudayalaya Limited</i>                  | 27.37% | 22.73%  |               |               |
|               | <i>Krishna Institute of Medical Sciences Limited</i> | 16.96% | 19.30%  |               |               |
|               | <i>Aster DM Healthcare Limited</i>                   | 3.63%  | 157.69% |               |               |
|               | <i>Rainbow Children's Medicare Limited</i>           | 17.24% | 16.63%  |               |               |
| NAV per share | <b>Company*</b>                                      | 50.53  | 59.09   | Not Available | Not Available |
|               | <b>Peer Group &amp; Industry Avg**</b>               |        | 169.49  | Not Available | Not Available |
|               | <i>Apollo Hospitals Enterprise Limited</i>           | 481.93 | 571.15  |               |               |
|               | <i>Max Healthcare Institute Limited</i>              | 86.54  | 96.50   |               |               |
|               | <i>Fortis Healthcare Limited</i>                     | 101.48 | 118.11  |               |               |
|               | <i>Global Health Limited</i>                         | 108.17 | 126.08  |               |               |
|               | <i>Narayana Hrudayalaya Limited</i>                  | 141.98 | 177.45  |               |               |
|               | <i>Krishna Institute of Medical Sciences Limited</i> | 228.47 | 53.43   |               |               |
|               | <i>Aster DM Healthcare Limited</i>                   | 71.62  | 68.63   |               |               |
|               | <i>Rainbow Children's Medicare Limited</i>           | 124.03 | 144.58  |               |               |

#### Notes

- 1 All the financial information for listed industry peers is on a consolidated basis and is sourced from the financial information of such listed industry peer as at and for the year ended
- 2 Shares outstanding are as of September 30, 2024 apart from Narayana Hrudayalaya Limited where shares outstanding are as of December 31, 2024.
- 3 Subsequent to the year ended March 31, 2024, the effect of stock split has been adjusted retrospectively presented for peers.
- 4 P/E ratio for the listed industry peers has been computed based on the closing market price of equity shares on BSE Limited ("BSE") as on January 15, 2024 divided by the diluted
- 5 Return on Net Worth (%) is calculated as profit for the year attributable to the owners of our Company divided by the Net Worth at the end of the respective year.
- 6 Net asset value (NAV) per equity share (book value per equity share) represents net worth divided by weighted average number of shares as of March 31, 2024.
- 7 Net worth means aggregate of equity share capital, instruments entirely equity in nature and other equity excluding legal reserve, capital redemption reserve and other amalgamation
- 8 In the case of Max Healthcare Institute Limited, revenue from operations includes income from other network and partner healthcare facilities, namely Balaji Society, GM Modi Society,
- 9 Basic and Diluted EPS for Aster DM are for the continuing business operations only.

**14 Any other material information**

| <b>Particulars</b>                                                                                                                                         | <b>Date</b> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Announcement under Regulation 30 (LODR)-Investor Presentation                                                                                              | 29-May-25   |
| Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31, 2025                                                      | 28-May-25   |
| Commencement Of Operations - New Delhi                                                                                                                     | 27-May-25   |
| Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation                                                                               | 24-May-25   |
| Compliances-Reg.24(A)-Annual Secretarial Compliance                                                                                                        | 21-May-25   |
| Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And                                       | 20-May-25   |
| Announcement under Regulation 30 (LODR)-Monitoring Agency Report                                                                                           | 15-May-25   |
| Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS                                                                                           | 14-May-25   |
| Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS                                                                                           | 21-Apr-25   |
| Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018                                                                                   | 3-Apr-25    |
| Commencement Of Operations Of New Branch - Eluru                                                                                                           | 27-Mar-25   |
| Closure of Trading Window                                                                                                                                  | 27-Mar-25   |
| Commencement Of Operations Of A New Branch - Udhna                                                                                                         | 24-Mar-25   |
| Commencement Of Operations Of A New Branch - Dombivli                                                                                                      | 21-Mar-25   |
| Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015                                                                                            | 17-Mar-25   |
| Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015                                                                                            | 13-Mar-25   |
| Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015                                                                                            | 13-Mar-25   |
| Commencement Of Operations Of A New Branch - Gopalpatnam                                                                                                   | 12-Mar-25   |
| Commencement Of Operations Of A New Branch - Karimnagar                                                                                                    | 10-Mar-25   |
| Commencement Of Operations Of A New Branch - Virar                                                                                                         | 8-Mar-25    |
| Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011                                                                                              | 7-Mar-25    |
| Commencement Of Operations Of New Branches - Mysore And Siddipet                                                                                           | 6-Mar-25    |
| Commencement Of Operations Of A New Branch - Jaunpur                                                                                                       | 3-Mar-25    |
| Commencement Of Operations Of A New Branch                                                                                                                 | 27-Feb-25   |
| Commencement Of Operations Of A New Branch                                                                                                                 | 24-Feb-25   |
| Commencement Of Operations Of A New Branch                                                                                                                 | 21-Feb-25   |
| Commencement Of Operation Of A New Branch                                                                                                                  | 19-Feb-25   |
| Announcement under Regulation 30 (LODR)-Credit Rating                                                                                                      | 17-Feb-25   |
| Integrated Filing (Financial)                                                                                                                              | 15-Feb-25   |
| Outcome Of Board Meeting For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2024 | 14-Feb-25   |
| Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011                                                                                              | 14-Feb-25   |
| Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results                                                                     | 11-Feb-25   |
| Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011                                                                                              | 7-Feb-25    |
| Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011                                                                                              | 6-Feb-25    |
| Listing of Equity Shares of Dr. Agarwals Health Care Ltd                                                                                                   | 4-Feb-25    |

*Note: For further updates and information, please refer Stock Exchange websites*